Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics’ NASH Therapeutic Candidate
Patients treated with efruxifermin (AKR-001) showed improvements in markers of insulin sensitivity and lipoprotein metabolism; sustained exposure over time. SOUTH SAN FRANCISCO, Calif., July 21, 2020 Akero Therapeutics, Inc. (Nasdaq:…